Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 58-year-old man with ophiasis-pattern alopecia areata who showed significant hair regrowth after treatment with clobetasol and microneedling with triamcinolone.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study found that topical immunotherapy is effective for treating severe alopecia areata, though patient responses can vary, highlighting the importance of individualized treatment approaches and prolonged therapy to optimize outcomes.

In this study, both topical minoxidil and latanoprost were found to improve dermoscopic features of alopecia areata, with latanoprost showing superior effectiveness; minor side effects included erythema and itching.

In this clinical study, researchers reported that both sodium valproate-loaded nanospanlastics and topical corticosteroids showed comparable modest efficacy in treating patchy alopecia areata, recommending further investigation into sodium valproate's role combined with other therapies.

This study suggests that administering SH-MSCs gel might decrease IL-6 expression and increase TGF-β expression in alopecia-like rats, indicating potential for alopecia therapy.

This study found that diphenylcyclopropenone (DPCP) was more effective and better tolerated than dinitrochlorobenzene (DNCB) in promoting hair regrowth in patients with alopecia areata.

This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.

In this case study, the authors explored the management of ophiasis, a rare and challenging form of alopecia areata, in a 3-year-old boy using the Unani system of medicine, aiming to provide insights for treatment approaches.

This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.

In this case report, secukinumab therapy for spondyloarthritis was associated with the development of alopecia areata in a 46-year-old woman, which improved after discontinuing the medication.

This study found that combining topical calcipotriol with intralesional autologous PRP injection significantly reduced Severity of Alopecia Tool scores in patients with alopecia areata, more effectively than either treatment alone.

In this randomized controlled trial, researchers observed that topical clobetasol propionate 0.05% was significantly more effective than topical tacrolimus 0.1% for treating alopecia areata, with a higher treatment success rate of 74.2% versus 45.2%, suggesting clobetasol as a preferred first-line topical therapy.

In this study, adding intralesional platelet rich plasma to topical mometasone proved more effective and showed earlier improvement in treating alopecia areata compared to using topical mometasone alone.

This study concluded that 0.05% betamethasone dipropionate cream is more effective than other topical treatments for improving alopecia areata over 12 weeks.

This double-blinded randomized clinical trial found that combining topical vitamin D analog (calcipotriol) and intra-lesion PRP led to a greater reduction in hair loss severity in alopecia areata patients compared to either treatment alone, with significant improvements observed across all groups.

This study found that switching patients with alopecia areata unresponsive to topical clobetasol 17 propionate 0.05% to anthralin treatment led to improved treatment success.

Scalp Roller therapy helped improve hair growth in patients with hard-to-treat alopecia areata.

This review discusses various nail changes in alopecia areata and suggests that they may be more prevalent than previously recognized, impacting quality of life and potentially indicating disease progression.

This review explores the causes and mechanisms of alopecia areata and discusses current treatments, reporting no new clinical findings.

This article reviews recent updates on alopecia areata, focusing on its causes, clinical presentation, and treatment options, and provides treatment plans by patient age and disease extent, but reports no new clinical results.

This article reviews the diagnosis and management of alopecia areata but reports no new research findings.

This research focuses on alopecia areata, highlighting the psychological impact, especially of its variant alopecia areata incognita, and provides diagnostic and treatment tips, but does not report specific results.

This review discusses the various off-label treatments for alopecia areata, highlighting that these therapies may promote hair growth but are not curative.

In this report, a young Caucasian woman developed a hairy tongue as an unusual side effect during baricitinib therapy for severe alopecia areata, which was managed by daily toothbrush debridement.

This diagnostic discussion reports that diffuse alopecia areata was identified in a patient with diffuse hair loss, based on specific histopathological features observed in a biopsy.

Alopecia areata is a common autoimmune condition causing varying hair loss, diagnosed by specific patterns of inflammation around hair follicles, with several treatment options available.

This study surveyed dermatologists in Greece and Italy and found significant variability and challenges in the diagnosis and treatment of alopecia areata, including limited use of severity scores and diverse treatment approaches, particularly for special site involvement and chronic cases.

This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.

This review discusses evidence for alopecia areata treatments, highlighting their ability to stimulate hair growth but noting limited data on long-term efficacy and impact on quality of life.